Drugs / Recombinant Human Factor VIIa
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04543383 | Jul 2020 → Jun 2023 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Factor VIIa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04543383 ↗ |
| Known as | rFVIIa | “Recombinant Human Factor VIIa (rFVIIa)” NCT04543383 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Factor VIIa (rFVIIa)” NCT04543383 ↗ |
| Route | Intravenous | “rFVIIa will be administered intravenously.” NCT04543383 ↗ |